Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 9:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 33,093 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo Clear all
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder

NCT03169816
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Lorcaserin, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 24, 2026, 9:21 PM EDT
Active, not recruiting Phase 3 Interventional

A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

NCT07172516
View directory record Official record
Conditions
Bipolar Disorder, Bipolar Depression, Bipolar I Disorder, Bipolar II Disorder
Interventions
Azetukalner, Placebo
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
34
States / cities
Tucson, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 24, 2026, 9:21 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Human Neuregulin-1 to Treat Stable Chronic Heart Failure

NCT01251406
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
Placebo, rhNRG-1 Dose 1, rhNRG-1 Dose 2
Drug
Lead sponsor
Zensun Sci. & Tech. Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
La Jolla, California • Los Angeles, California • Tustin, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 24, 2026, 9:21 PM EDT
Terminated Phase 3 Interventional Results available

Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer

NCT02853604
View directory record Official record
Conditions
High Risk Cervical Cancer, Advanced Cervical Cancer
Interventions
ADXS11-001, Placebo
Drug
Lead sponsor
Advaxis, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
41
States / cities
Mobile, Alabama • Phoenix, Arizona • Duarte, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 24, 2026, 9:21 PM EDT
Completed Phase 1 Interventional Results available

Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea

NCT01579084
View directory record Official record
Conditions
Rosacea, Erythema
Interventions
AGN-199201 Formulation A, AGN-199201 Formulation B, AGN-199201 Formulation C, AGN-199201 Vehicle
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 24, 2026, 9:21 PM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

NCT01111552
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Escitalopram, Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Carson, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 24, 2026, 9:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of 4 Weeks of Citrulline and Glutathione Supplementation on Arterial Function

NCT04672447
View directory record Official record
Conditions
Menopause, Cardiovascular Risk Factor
Interventions
L-Citrulline, Placebo, Glutathione
Dietary Supplement
Lead sponsor
Texas Tech University
Other
Eligibility
50 Years to 79 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 24, 2026, 9:21 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes

NCT00954447
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Linagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
47
States / cities
Escondido, California • Fresno, California • Greenbrae, California + 42 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2013 · Synced Oct 24, 2026, 9:21 PM EDT
Completed Not applicable Interventional Results available

TrueRelief Efficacy for Post-cesarean Pain (ELECTRON)

NCT05250830
View directory record Official record
Conditions
Post-cesarean Pain
Interventions
TrueRelief device, Sham TrueRelief device
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 24, 2026, 9:21 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Clinical Study to Assess the Effects of Prebiotic and Probiotic Supplement

NCT06794619
View directory record Official record
Conditions
Healthy
Interventions
Placebo, Dietary Supplement with actives
Dietary Supplement
Lead sponsor
Olly, PBC
Industry
Eligibility
18 Years to 50 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Oct 24, 2026, 9:21 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults

NCT02771730
View directory record Official record
Conditions
Healthy Volunteer, HIV Vaccine
Interventions
Ad4-mgag, Ad4-EnvC150, Placebo Comparator, AIDSVAX B/E
Biological · Other
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 49 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 24, 2026, 9:21 PM EDT
Completed Early Phase 1 Interventional Results available

MEG Study of Acute STX209 Effects in ASD

NCT02278328
View directory record Official record
Conditions
Autism Disorder
Interventions
STX209 (15mg), placebo, STX209 (30mg)
Drug
Lead sponsor
Timothy Roberts
Other
Eligibility
14 Years to 17 Years · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Oct 24, 2026, 9:21 PM EDT
Completed Phase 1Phase 2 Interventional Results available

IL1-TRAP, Rilonacept, in Systemic Sclerosis

NCT01538719
View directory record Official record
Conditions
Scleroderma, Systemic Sclerosis, Diffuse Scleroderma, Diffuse Systemic Sclerosis
Interventions
Rilonacept, Placebo
Drug · Other
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 24, 2026, 9:21 PM EDT
Completed Not applicable Interventional

Automated Telehealth Diagnostics for Remote Parkinson Monitoring

NCT02152319
View directory record Official record
Conditions
Parkinson's Disease
Interventions
KHV reporting, Standard care
Device · Procedure
Lead sponsor
Great Lakes NeuroTechnologies Inc.
Industry
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Oct 24, 2026, 9:21 PM EDT
Completed No phase listed Observational

Long-term Effects of Dutasteride on Architectural and Nuclear Morphometric Features of Benign Prostate Tissue

NCT01473030
View directory record Official record
Conditions
Benign Prostate Tissue
Interventions
Not listed
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
50 Years to 75 Years · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 24, 2026, 9:21 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis

NCT02295865
View directory record Official record
Conditions
Psoriasis
Interventions
JNJ-38518168 60 mg, JNJ-38518168 30 mg, JNJ-38518168 3 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Los Angeles, California • Santa Monica, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2017 · Synced Oct 24, 2026, 9:21 PM EDT
Completed Phase 2Phase 3 Interventional Results available

BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT)

NCT01903265
View directory record Official record
Conditions
Primary Fibromyalgia
Interventions
TNX-102 SL 2.8mg, Placebo
Drug
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
17
States / cities
Sacramento, California • Denver, Colorado • Brooksville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2016 · Synced Oct 24, 2026, 9:21 PM EDT
Completed Phase 4 Interventional Results available

Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance

NCT00400400
View directory record Official record
Conditions
Renal Transplantation
Interventions
Enteric-coated mycophenolate sodium (EC-MPS), Mycophenolate mofetil, Placebo to mycophenolate sodium, Placebo to mycophenolate mofetil
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
53
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2011 · Synced Oct 24, 2026, 9:21 PM EDT
Completed Phase 4 Interventional

Safety of Ramelteon in Subjects With Chronic Obstructive Pulmonary Disease

NCT00316992
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Ramelteon and Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
40 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Santa Monica, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2010 · Synced Oct 24, 2026, 9:21 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Coenzyme Q10 in Older Athletes Treated With Statin Medications

NCT01026311
View directory record Official record
Conditions
Muscle Weakness, Myalgia, Side Effects of Statins
Interventions
Coenzyme q 10, placebo
Drug
Lead sponsor
Richard Deichmann, MD
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Oct 24, 2026, 9:21 PM EDT
Terminated Phase 2 Interventional Results available

Saved From COVID-19 - Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID

NCT04349371
View directory record Official record
Conditions
COVID, Coronavirus Infection
Interventions
Chloroquine, Placebo oral tablet
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 24, 2026, 9:21 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease

NCT03870334
View directory record Official record
Conditions
Crohn's Disease
Interventions
BT-11 880 mg, Placebo
Drug
Lead sponsor
NImmune Biopharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Oct 24, 2026, 9:21 PM EDT
Completed Phase 4 Interventional Results available

Clinical and Imaging Trial of Uridine for Veterans With Suicidal Ideation

NCT03265964
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Uridine, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 55 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 24, 2026, 9:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cannabidiol and Emotional Stimuli

NCT02902081
View directory record Official record
Conditions
Drug Addiction
Interventions
Cannabidiol, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 35 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 24, 2026, 9:21 PM EDT